AstraZeneca plans to spend $50 billion on U.S. manufacturing and research through 2030, including a new $4 billion facility in Virginia, aiming to expand drug production, R&D, and cell therapy capabilities across multiple states. The investment supports AstraZeneca’s goal of achieving $80 billion in annual revenue with half generated in the U.S. The initiative reflects industry trends amid U.S. tariff discussions that encourage domestic pharma manufacturing for national security.